Circumventing cancer drug resistance in the era of personalized medicine.
about
Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture ModelsWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibThe next steps in next-gen sequencing of cancer genomesCancer evolution: mathematical models and computational inferencePrimary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesPreclinical mouse cancer models: a maze of opportunities and challenges.In vitro selection of mutant HDM2 resistant to Nutlin inhibitionDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Response and acquired resistance to everolimus in anaplastic thyroid cancerTargeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentMouse models of colorectal cancer as preclinical modelsAutophagy in thyroid cancer: present knowledge and future perspectivesLoss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cellsLeveraging systems biology approaches in clinical pharmacologyIdentifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discoveryReverse Chemical Genetics: Comprehensive Fitness Profiling Reveals the Spectrum of Drug Target InteractionsA novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent mannerTumour heterogeneity and cancer cell plasticityHarnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell linesUnderstanding Drug Resistance in Breast Cancer with Mathematical OncologyTargeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.The quest to overcome resistance to EGFR-targeted therapies in cancer.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Next-generation cDNA screening for oncogene and resistance phenotypes.Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.Attacking the supply wagons to starve cancer cells to death."Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features.Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature.ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients.Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.A functional landscape of resistance to ALK inhibition in lung cancer.Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474Novel molecular targets for urothelial carcinoma
P2860
Q26797285-60726D3E-F971-4395-801D-DE210D2CEFDCQ26825780-A04A696E-2F3C-4631-8ACF-DCBD5FB9A61EQ26866517-A096DA4E-CC71-4F88-8A66-041C43ADC61DQ26995113-28ED5B95-5158-41DE-85A5-3E8B09C0418DQ26998894-92BA4CEF-6D80-4374-A9A4-B2698DC80044Q27002537-1D4878CC-E33B-495B-B0E3-2F33BB28C41DQ27015224-0B9B7E8D-6043-4F83-BED7-F37C4BA6EC87Q27322080-CDD68917-9C84-4141-A3FD-269D90C95504Q27322456-AEBF9FC0-1B42-431A-A2C6-E3B5397CFF69Q27692033-CCDFF302-9C26-4516-A6B5-A7C9F18F893FQ27853005-17D3C384-0400-4771-AC71-81C1E537C274Q27853080-034D060A-EA07-423E-A4EB-3D7A85010C01Q28076462-544BC101-147E-4A4F-BAE7-CDC1BB61ED2EQ28081871-0350D58B-B485-4834-B8B5-B34D4E32EED6Q28086785-0D210E42-5369-40E5-9956-C9634794FD73Q28481370-0196B2D3-E0B1-422A-B2B0-0883AFF6A7B7Q28539118-62F75319-5485-4FF0-9B03-7CD66E29EC82Q28540918-75E95881-1721-46A2-8E2F-30D9528A188AQ28553891-AB461D01-D052-4AA3-9696-3765B3EE3F6FQ28817145-9DE1C586-B0A2-4928-822D-29C44D739681Q29617990-5106C4A3-01A1-49DC-9ACD-894580A7270CQ30384542-DD52D66C-03AB-4AC7-AF2E-3CDE09435318Q33586758-5A45C3E6-BEF7-487E-8623-A9802D5617F3Q33597596-1213283E-39C9-4DCF-8FE2-288E241BA62EQ33690336-84065D9E-85C3-4500-BBB2-F93509E9333AQ33725972-B5CF48B3-F3C0-4231-A2CE-337B5417F18BQ33725976-3BEE33F9-2272-4D5E-B8FF-BE2CA563E728Q33726782-A660F5EE-568F-4D1E-80A0-CC6299D0080EQ34474239-C65B4738-3321-4485-B211-3544BE3313F1Q34489987-69A9C221-B167-40EC-922A-015CB011B303Q34516773-1C30472F-052F-4C66-9F76-ADEBB09A3EC7Q34608734-47CC4F9C-CB4B-44EE-969C-1842AEBE4618Q34619336-A138B593-3DA8-4520-961D-218FBCAEDB71Q35004013-667FB9DF-6EA6-4496-94DA-6C4432BDD76FQ35200483-BDC84FD8-B745-4223-9C30-5B25B23A83CFQ35337927-8AB12A59-7630-4993-8434-0D82A87B5678Q35412202-945DBE92-64C4-4D21-8B27-0833E8D6B9BDQ35438912-71127376-0D88-40F6-9B3C-8F08C44A2739Q35439316-70915F66-F1A7-4821-A628-E800CA09CE5AQ35527068-86B39BC0-75D2-4502-B94E-D70583D61CAC
P2860
Circumventing cancer drug resistance in the era of personalized medicine.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Circumventing cancer drug resistance in the era of personalized medicine.
@ast
Circumventing cancer drug resistance in the era of personalized medicine.
@en
Circumventing cancer drug resistance in the era of personalized medicine.
@nl
type
label
Circumventing cancer drug resistance in the era of personalized medicine.
@ast
Circumventing cancer drug resistance in the era of personalized medicine.
@en
Circumventing cancer drug resistance in the era of personalized medicine.
@nl
prefLabel
Circumventing cancer drug resistance in the era of personalized medicine.
@ast
Circumventing cancer drug resistance in the era of personalized medicine.
@en
Circumventing cancer drug resistance in the era of personalized medicine.
@nl
P1433
P1476
Circumventing cancer drug resistance in the era of personalized medicine.
@en
P304
P356
10.1158/2159-8290.CD-12-0012
P577
2012-02-28T00:00:00Z